Zynext Ventures

Feldan Therapeutics is a biopharmaceutical company focused on developing innovative treatments using its proprietary peptide-based technology platform, known as the Feldan Shuttle. This platform facilitates fast and safe intracellular delivery, allowing access to cellular components that are typically unreachable by conventional drugs. By leveraging the unique characteristics of the Feldan Shuttle, the company aims to create a new generation of therapeutic applications, as evidenced by its ongoing pipeline of clinical programs. Feldan Therapeutics is committed to advancing the field of intracellular therapeutics to improve patient outcomes.

Illexcor Therapeutics is a biopharmaceutical firm dedicated to creating and developing groundbreaking oral treatments for sickle cell disease.

Neuro42 is focused on developing and commercializing advanced magnetic resonance imaging (MRI) and robotics technology aimed at diagnosing and guiding interventions for neurological conditions. The company has created portable MRI machines designed to enhance the diagnostic process for various brain issues, including traumatic injuries, epilepsy, and tumors. By providing imaging solutions that facilitate triaging, screening, and direct robotic interventions, Neuro42 aims to improve patient care, particularly for those who have suffered strokes. This innovative approach shifts the point of care from traditional MRI suites to more accessible settings, enabling timely and effective treatment for neurological conditions.